We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of MK-6913 for the Treatment of Hot Flashes in Postmenopausal Women (6913-004)

This study has been terminated.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01015677
First Posted: November 18, 2009
Last Update Posted: July 2, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.
  Purpose
This study will assess the safety, tolerability, and efficacy of MK-6913 for the treatment of moderate-to-very-severe vasomotor symptoms (hot flashes or hot flushes) in postmenopausal women. The primary study hypothesis is that one or more doses of MK-6913 will result in a significantly greater reduction from baseline, compared to placebo, in the number of moderate to very severe hot flashes after 4 weeks of treatment.

Condition Intervention Phase
Moderate to Severe Vasomotor Symptoms in Postmenopausal Women Drug: MK-6913 Drug: 17-β estradiol Drug: Placebo to MK-6913 Drug: Placebo to 17-β estradiol Drug: MK-6913 25 mg Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Phase IIa, Randomized, Double-Blind, Placebo- and Active-Controlled Study to Examine MK-6913 for the Treatment of Vasomotor Symptoms in Postmenopausal Women

Further study details as provided by Merck Sharp & Dohme Corp.:

Primary Outcome Measures:
  • Percent Change From Baseline in the Number of Weekly Moderate to Very Severe Hot Flashes (Excluding Outliers) at Week 4 [ Time Frame: Baseline and Week 4 ]
    Hot flashes were recorded in real time and hot flashes recorded retrospectively in the morning and evening reports in a diary day via the Hot Flash e-diary were summed to determine the total number of hot flashes over a diary day. The total number of weekly moderate or worse hot flashes were calculated as the sum of the total number of hot flashes that occur over a diary week (non-missing diary day), divided by the number of days of diary completion, and multiplied by 7 (standardized week). At least 4 non-missing diary days were required to define the total number of weekly moderate or worse hot flashes. Hot flash data was excluded for participants whose number of moderate to severe hot flashes per week were in the top 1% of number of hot flashes reported to exclude any outlier effect.

  • Number of Participants Who Experienced at Least One or More Adverse Events (AE) [ Time Frame: Up to 6 weeks ]
    An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.

  • Number of Participants Who Discontinued Study Drug Due to an AE [ Time Frame: Up to 4 weeks ]
    An adverse event (AE) is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.


Secondary Outcome Measures:
  • Percent Change From Baseline in the Weekly Hot Flash Severity Score (Combining Severe and Very Severe Score) at Week 4 [ Time Frame: Baseline and Week 4 ]
    Hot flash severity score is calculated by the sum of: the number of mild hot flashes, 2 times number of moderate hot flashes, 3 times the number of severe hot flashes, and 4 times the number of very severe hot flashes. This sum was standardized to a 7-day week if there were any missing days in the e-diary. The severity of each hot flash was recorded by the Hot Flash e-diary.

  • Change From Baseline in Follicle-stimulating Hormone (FSH) Level at Week 4 [ Time Frame: Baseline and Week 4 ]
    FSH was measured to assess estrogen receptor (ER) selectivity (a biomarker for ERα activity and a pharmacodynamic endpoint).


Enrollment: 99
Actual Study Start Date: December 17, 2009
Study Completion Date: July 30, 2010
Primary Completion Date: July 30, 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: MK-6913 75 mg
MK-6913 75 mg capsule and matching placebo for 17β-estradiol 1 mg tablet once daily for 4 weeks (Stage 1 and Stage 2)
Drug: MK-6913 Drug: Placebo to 17-β estradiol
Active Comparator: 17-β estradiol 1 mg
17β-estradiol 1 mg tablet and matching placebo for MK-6913 75 mg capsule once daily for 4 weeks (Stage 1 and Stage 2)
Drug: 17-β estradiol Drug: Placebo to MK-6913
Placebo Comparator: Placebo
Matching placebo for MK-6913 75 mg capsule and matching placebo for 17β-estradiol 1 mg tablet once daily for 4 weeks (Stage 1 and State 2)
Drug: Placebo to MK-6913 Drug: Placebo to 17-β estradiol
Experimental: MK-6913 25 mg
MK-6913 25 mg capsule and matching placebo for 17β-estradiol 1 mg tablet once daily for 4 weeks (Stage 2)
Drug: MK-6913 25 mg

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   35 Years to 60 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Woman with at least 50 moderate to very severe hot flash episodes per week
  • Postmenopausal
  • Between 45 and 60 years of age if naturally menopausal, or between 35 and 60 if she underwent a bilateral oophorectomy
  • Not receiving hormone therapy
  • Has had both a normal mammogram and a normal Pap test in the past 6 months
  • Generally healthy

Exclusion Criteria:

  • A history of cancer, except for certain skin cancers
  • Undiagnosed vaginal bleeding or any uterine endometrial disorder
  • Currently uses tobacco products, or has used them in the last 6 months
  • Has human immunodeficiency virus (HIV)
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01015677


Sponsors and Collaborators
Merck Sharp & Dohme Corp.
Investigators
Study Director: Medical Monitor Merck Sharp & Dohme Corp.
  More Information

Study Data/Documents: CSR Synopsis  This link exits the ClinicalTrials.gov site

Responsible Party: Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier: NCT01015677     History of Changes
Other Study ID Numbers: 6913-004
MK-6913-004 ( Other Identifier: Protocol number )
First Submitted: November 17, 2009
First Posted: November 18, 2009
Results First Submitted: February 26, 2016
Results First Posted: May 4, 2016
Last Update Posted: July 2, 2017
Last Verified: June 2017

Additional relevant MeSH terms:
Estradiol
Polyestradiol phosphate
Estradiol 3-benzoate
Estradiol 17 beta-cypionate
Estradiol valerate
Estrogens
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Contraceptive Agents
Reproductive Control Agents
Contraceptive Agents, Female